CDEK
← All drugs Report issue

atagabalin

Small moleculeexperimental

Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels. It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. — Wikipedia

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2007 (NCT00569972)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1CC(CN)(CC(=O)O)C[C@@H]1C
Mol. weight
185.27 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • (1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid
  • atagabalin
  • atagabalin
  • atagabalin
  • pd0200390
  • pd 0200390
  • pd 0200390
  • pd 0200390
  • pd-0200390
  • pd-0200390
  • pd-0200390

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00748592Phase 2Jan 1, 2009Pfizer
NCT00722306Phase 1May 1, 2008Pfizer
NCT00655369Phase 2Apr 1, 2008Pfizer
NCT00551148Phase 2Oct 1, 2007Pfizer
NCT00569972Phase 2Oct 1, 2007Pfizer
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit5522007
1 organizations
Page 1 / 1